Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek sales stable, inventory destocking looms

This article was originally published in The Tan Sheet

Executive Summary

The maker of life'sDHA reports second quarter revenues inched up 1.9 percent to $92.4 million, despite a 1.3 percent dip in infant formula sales to $77.4 million. Martek Biosciences set records for revenues and pretax profits during the quarter ended April 30, reporting 19.7 percent growth in net income to $11 million over the year-ago period. The Columbia, Md.-based nutritional oils firm said during a June 3 earnings call it expects a $10 million to $15 million revenue hit due to destocking of infant formula during its fiscal 2009 third and fourth quarters. CEO Steve Dubin expects the destocking to be temporary and infant formula sales growth should resume in 2010

You may also be interested in...



Martek looks beyond infant formulas

The maker of life'sDHA nutritional additive plans to overcome a drop in the U.S. birthrate by growing in global markets and conventional food applications. Martek Biosciences reported third-quarter revenues fell 12 percent to $77.8 million mainly due to inventory destocking, which the Columbia, Md., firm predicted (1"The Tan Sheet" June 8, 2009, In Brief). Martek's infant formula sales fell 15.4 percent, to $63.3 million, in the May-July period, although its pregnancy and nursing, nutritional supplements and animal feeds businesses shot up 58 percent to $7.9 million. Third-quarter net income dipped 4.3 percent to $8.9 million, Martek reported Sept. 2. ... DHA patents prevail: A ruling by the U.S. Court of Appeals for the Federal Circuit supports certain Martek patents on the process of extracting lipids from fermented microorganisms to produce DHA. Martek previously asserted that Swiss ingredients manufacturer Lonza infringed its patents, which Lonza said were invalid. In a Sept. 3 2decision, the court remands the case

Beximco And Mylan Strike Biosimilars Deal

Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.

GSK Offloads Physiogel In North America, Asia To Korea’s LG

GSK will raise around £125m from the sale of skin-care brand Physiogel to LG Household & Healthcare to finance the integration of Pfizer Consumer Healthcare. 

Topics

UsernamePublicRestriction

Register

PS102997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel